Search by PDG name  
   

 

TYMS  
    


    
      Official symbol:  TYMS
      Full name:  thymidylate synthetase
      Location:  18p11.32
      Also known as:  HsT422, TS, Tsase, TMS
      Entrez ID:  7298
      Ensembl ID:  ENSG00000176890
      Summary:  Thymidylate synthase catalyzes the methylation of deoxyuridylate to deoxythymidylate using, 10-methylenetetrahydrofolate (methylene-THF) as a cofactor. This function maintains the dTMP (thymidine-5-prime monophosphate) pool critical for DNA replication and repair. The enzyme has been of interest as a target for cancer chemotherapeutic agents. It is considered to be the primary site of action for 5-fluorouracil, 5-fluoro-2-prime-deoxyuridine, and some folate analogs. Expression of this gene and that of a naturally occurring antisense transcript, mitochondrial enolase superfamily member 1 (GeneID:55556), vary inversely when cell-growth progresses from late-log to plateau phase. Polymorphisms in this gene may be associated with etiology of neoplasia, including breast cancer, and response to chemotherapy. [provided by RefSeq, Aug 2017]

    

    
  Overall distribution
    
  Tissue specific distribution
    
 
  
 
Expression restricted in 12 cancer type(s)
Cancer specific in breast cancer subtype (Basal; LumB; TNBC)
   

    
  Overall distribution
    
  Tissue specific distribution
    
 
Gscore (Amp):  0.18  
Gscore (Del):  0.12  
 
Recurrently amplified in 1 cancer type(s)
Recurrently deleted in 1 cancer type(s)
   

    
  Overall distribution
    
  Tissue specific distribution
    
 
Mscore:  0.00  
 
   

    
  Overall
    
  Tissue specific
    
 
Total fusion occurrence:  1  
 
Fusions detected in 1 cancer type(s)
 
 

    
  Overall
    
  Tissue specific
    
   CRISPR: STRONGLY SELECTIVE 
 RNAi: STRONGLY SELECTIVE 
   
   

    
      Functional class:  Enzyme
      JensenLab PubMed score:  732.02  (Percentile rank: 93.50%)
      PubTator score:  609.54  (Percentile rank: 94.47%)
      Target development/druggability level:  TclinThese targets have activities in DrugCentral (ie. approved drugs) with known mechanism of action.
      Tractability (small molecule):  Clinical PrecedenceTargets with drugs in phase II or above; Pre-clinical targets
      Tractability (antibody):  

    







Contact us | | Terms & Conditions.
Copyright © 2020 University of Pennsylvania. All Rights Reserved.